Figure 8.

(A) Schematic illustration of the Ang-LiB(T+an@siTGF-β) component and delivery strategy [60]. (B) In vitro BBB model to investigate the BBB-crossing ability of Ang-LiB(T+an@siTGF-β). (C) The cytotoxicity of GL261 cells after different treatments. (D) Percent survival of orthotopic GL261-bearing mice after different treatments. (E) In vivo MR imaging of GL261-bearing mice after injection of LiB(T+an@siTGF-β) and Ang-LiB(T+an@siTGF-β). Reproduced with permission [60]. Copyright 2018, John Wiley, and Sons. MR, magnetic resonance; NPs, nanoparticles